Experts has a new look! Let us know what you think of the updates.

Provide feedback
Home
Scholarly Works
Mortality Benefit of Rivaroxaban Plus Aspirin in...
Journal article

Mortality Benefit of Rivaroxaban Plus Aspirin in Patients With Chronic Coronary or Peripheral Artery Disease

Abstract

BACKGROUND: The combination of 2.5 mg rivaroxaban twice daily and 100 mg aspirin once daily compared with 100 mg aspirin once daily reduces major adverse cardiovascular (CV) events in patients with chronic coronary artery disease (CAD) or peripheral artery disease (PAD). OBJECTIVES: The aim of this work was to report the effects of the combination on overall and cause-specific mortality.

Authors

Eikelboom JW; Bhatt DL; Fox KAA; Bosch J; Connolly SJ; Anand SS; Avezum A; Berkowitz SD; Branch KRH; Dagenais GR

Journal

Journal of the American College of Cardiology, Vol. 78, No. 1, pp. 14–23

Publisher

Elsevier

Publication Date

July 2021

DOI

10.1016/j.jacc.2021.04.083

ISSN

0735-1097